Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.
Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study
Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.
Exact Sciences: Cost Optimization And Product Strength
Exact Sciences stock is down 35% since August 2021, now trading at around $58.75. The second quarter of 2024 (Q2) results beat expectations with revenue growth driven by the Cologuard screening segment. It raised adjusted EBITDA guidance for 2024, demonstrating confidence in continued sales momentum and profitability.
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.
Wall Street Analysts Predict a 45.04% Upside in Exact Sciences (EXAS): Here's What You Should Know
The consensus price target hints at a 45% upside potential for Exact Sciences (EXAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Exact Sciences Analysts Slash Their Forecasts After Q2 Results
Exact Sciences Corporation EXAS reported better-than-expected second-quarter financial results on Wednesday.
Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat
Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.
Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat
Exact Sciences stock bounded higher Thursday after beating second-quarter expectations, signaling a return to growth for Cologuard.
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.
Exact Sciences Corporation (EXAS) Q2 2024 Earnings Call Transcript
Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Erik Holznecht - Manager, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Tycho Peterson - Jefferies Andrew Brackman - William Blair Catherine Schulte - Baird Matt Sykes - Goldman Sachs Dan Arias - Stifel Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Jack Meehan - Nephron Research Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Operator Thank you for standing by. At this time, I would like to welcome everyone to today's Exact Sciences Second Quarter 2024 Earnings Call.
The Single Best Stock to Buy Under $50
24/7 Wall Street Insights Early cancer detection is the first line of defense in preventing the disease's progression and reducing fatalities.
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
